Q1

JAMAICA BROILERS GROUP LIMITED

# INTERIM REPORT

2 AUGUST 2025 | 3 MONTHS | QUARTER ONE



The Best Dressed Chicken Cogeneration Facility is now powered by a 6.5MW Hyundai engine generating cleaner, more efficient energy.

# FIRST QUARTER REPORT

2025/2026 FINANCIAL YEAR | THREE MONTHS | UNAUDITED RESULTS

## INTERIM REPORT TO OUR SHAREHOLDERS

The Directors of Jamaica Broilers Group Limited now release the unaudited financial results for the quarter ended August 2, 2025 which have been prepared in accordance with International Financial Reporting Standards (IFRS).

The Group's operations produced a net profit of $1.6 billion for the three months ended August 2, 2025 compared to the restated net profit of $284 million for the three months ended July 27, 2024. Group revenues for the first quarter amounted to $26.2 billion, a 12% increase above the $23.5 billion achieved in the corresponding quarter of the previous year. Our gross profit for the quarter was $6.2 billion, a 35% decrease from the corresponding quarter.

Jamaica Operations reported a segment result of $2.1 billion which was $526 million or 33% above last year's segment result. Total revenue for our Jamaica Operations showed an increase of 4% for the corresponding quarter. The increase was mainly driven by increased poultry sales over the prior year.

Our US Operations reported a segment result of $612 million, which is $406 million above last year's restated segment results. Total revenue for the US Operations showed an increase of 19% over the corresponding quarter, driven by increased sales of poultry and fertile eggs.

The Group has now completed a revaluation of certain assets in accordance with IFRS. The revaluation resulted in an increase of approximately $40 billion, to the carrying value of these assets to better reflect their current fair market value. The revaluation will be reflected in the company's financial statements for the quarter ended November 1, 2025, reinforcing the company's strong financial position and long-term asset base.

The Staff, Management and the Board of Directors of Jamaica Broilers Group Limited continue to trust in the Lord's guidance for our company and are grateful for His Blessings and Provision.

Robert Levy
**Chairman**

Christopher Levy
**Group President & CEO**

November 13, 2025

| | Quarter ended 2 August 2025 $'000 | Restated Quarter ended 27 July 2024 $'000 |
|---|---|---|
| **Revenue** | 26,188,529 | 23,456,470 |
| Cost of sales | (20,021,100) | (18,900,526) |
| **Gross Profit** | 6,167,429 | 4,555,944 |
| Other income | 486,804 | 54,775 |
| Distribution costs | (1,531,465) | (737,399) |
| Administration and other expenses | (2,509,727) | (2,893,320) |
| **Operating Profit** | 2,613,041 | 980,000 |
| Finance income | 46,610 | 22,595 |
| Finance costs | (951,673) | (653,025) |
| **Profit before Taxation** | 1,707,978 | 349,570 |
| Taxation | (112,702) | (65,972) |
| **Net Profit** | 1,595,276 | 283,598 |
| **Other Comprehensive Income, net of taxes -** | | |
| **Item that will be reclassified to profit or loss -** | | |
| Exchange differences on translating foreign operations | (126,516) | (11,131) |
| Total other comprehensive income | (126,516) | (11,131) |
| **Total Comprehensive Income** | 1,468,760 | 272,467 |
| | $ | $ |
| **Earnings per Stock Unit** | 1.47 | 0.29 |

# JAMAICA BROILERS GROUP LIMITED

## GROUP BALANCE SHEET

2 AUGUST 2025

(expressed in Jamaican dollars unless otherwise indicated)

| | 2 August 2025 $'000 Unaudited | 3 May 2025 $'000 Audited | 27 July 2024 $'000 Unaudited |
|---|---|---|---|
| **Non-Current Assets** | | | |
| Property, plant and equipment | 21,512,800 | 22,185,969 | 22,497,781 |
| Right of use assets | 816,189 | 762,264 | 844,965 |
| Intangible assets | 2,266,224 | 2,347,380 | 2,279,331 |
| Investment property | 5,107 | 5,149 | 5,274 |
| Investments | 338,059 | 335,775 | 347,208 |
| Loans receivable | 610,540 | 610,860 | - |
| Deferred income taxes | 24,066 | 24,066 | 27,301 |
| Post-employment benefit assets | - | - | 973,357 |
| Total Non-Current Assets | 25,572,985 | 26,271,463 | 26,975,217 |
| **Current Assets** | | | |
| Inventories | 12,028,761 | 10,785,763 | 10,118,108 |
| Biological assets | 8,223,817 | 8,036,240 | 7,022,789 |
| Receivables | 8,348,491 | 7,020,801 | 6,263,456 |
| Taxation recoverable | 1,894,137 | 1,338,779 | 684,975 |
| Financial assets at fair value through profit or loss | 196,446 | 184,543 | 182,359 |
| Cash and short-term investments | 645,761 | 1,104,099 | 3,178,438 |
| **Total Current Assets** | 31,337,413 | 28,470,225 | 27,450,125 |
| **Current Liabilities** | | | |
| Payables | 18,389,513 | 18,368,073 | 15,347,955 |
| Liabilities under supplier financing | 1,268,187 | 1,660,036 | 1,264,049 |
| Taxation payable | 664,047 | 597,545 | 70,153 |
| Borrowings | 43,223,629 | 42,197,697 | 36,545,468 |
| Lease liabilities | 287,912 | 231,144 | 382,704 |
| Total Current Liabilities | 63,833,288 | 63,054,495 | 53,610,329 |
| **Net Current Liabilities** | (32,495,875) | (34,584,270) | (26,160,204) |
| Capital Employed | (6,922,890) | (8,312,807) | 815,013 |
| **Stockholders' Equity** | | | |
| Share capital | 765,137 | 765,137 | 765,137 |
| Reserves | 2,287,901 | 2,414,417 | 2,617,246 |
| Retained earnings | (7,706,078) | (9,301,354) | (228,454) |
| Shares held by Trust | (3,912,968) | (3,912,968) | (3,902,591) |
| Total Stockholders' Equity | (8,566,008) | (10,034,768) | (748,662) |
| **Non-Current Liabilities** | | | |
| Borrowings | 260,350 | 270,127 | 202,809 |
| Lease liabilities | 584,709 | 579,919 | 435,289 |
| Deferred income taxes | 409,418 | 483,274 | 915,033 |
| Post-employment benefit obligations | 388,641 | 388,641 | 10,544 |
| Total Non-Current Liabilities | 1,643,118 | 1,721,961 | 1,563,675 |
| Total equity and non-current liabilities | (6,922,890) | (8,312,807) | 815,013 |

Robert Levy
**Chairman**

Christopher Levy
**Group President & CEO**

November 13, 2025

| | Attributable to the Company's Stockholders | | | | | |
|---|---|---|---|---|---|---|
| | Number of Shares | Share Capital | Reserves | Retained Earnings | Shares held by Trust | Total Equity |
| | '000 | $'000 | $'000 | $'000 | $'000 | $'000 |
| Balance at 27 April 2024 | 1,001,466 | 765,137 | 3,207,966 | 30,729,788 | (3,902,591) | 30,800,300 |
| Restatement | - | - | (579,589) | (31,241,840) | - | (31,821,429) |
| Balance at 27 April 2024 as restated | 1,001,466 | 765,137 | 2,628,377 | (512,052) | (3,902,591) | (1,021,129) |
| Other comprehensive income | - | - | (11,131) | - | - | (11,131) |
| Net profit | - | - | - | 283,598 | - | 283,598 |
| Comprehensive income | - | - | (11,131) | 283,598 | - | 272,467 |
| Balance at 27 July 2024 | 1,001,466 | 765,137 | 2,617,246 | (228,454) | (3,902,591) | (748,662) |
| Balance at 3 May 2025 | 1,001,169 | 765,137 | 2,414,417 | (9,301,354) | (3,912,968) | (10,034,768) |
| Other comprehensive income | - | - | (126,516) | - | - | (126,516) |
| Net profit | - | - | - | 1,595,276 | - | 1,595,276 |
| Comprehensive income | - | - | (126,516) | 1,595,276 | - | 1,468,760 |
| Balance at 2 August 2025 | 1,001,169 | 765,137 | 2,287,901 | (7,706,078) | (3,912,968) | (8,566,008) |

| | Quarter ended 2 August 2025 $'000 | Restated Quarter ended 27 July 2024 $'000 |
|---|---|---|
| **Cash Flows from Operating Activities** | | |
| Net profit | 1,595,276 | 283,598 |
| Adjustments for: | | |
| Depreciation | 286,242 | 508,778 |
| Amortisation | 87,908 | 24,368 |
| Deferred expenditure | | - |
| Fair value gains on financial assets at fair value through profit or loss | (5,619) | (7,757) |
| Gain on disposal of property, plant and equipment | (367,510) | - |
| Taxation expense | 112,702 | 65,972 |
| Interest income | (9,280) | (9,037) |
| Unrealised foreign exchange losses | 75,337 | 11,724 |
| Interest expense | 854,945 | 655,794 |
| | 2,630,001 | 1,533,440 |
| Changes in operating assets and liabilities: | | |
| Inventories | (1,235,260) | (252,795) |
| Biological assets | (127,624) | 5,441 |
| Receivables | (1,302,274) | 2,309,299 |
| Payables | 76,015 | (3,150,912) |
| Financial assets at fair value through profit or loss | (4,322) | (1,565) |
| | 36,536 | 442,908 |
| Taxation paid | (660,856) | (382,078) |
| **Cash (used in)/provided by operating activities carried forward** | (624,320) | 60,830 |

| | Quarter ended 2 August 2025 $'000 | Restated Quarter ended 27 July 2024 $'000 |
|---|---|---|
| **Cash Flows (used in)/provided by Operating Activities** | (624,320) | 60,830 |
| **Cash Flows from Investing Activities** | | |
| Purchase of property, plant and equipment | (339,765) | (1,005,396) |
| Proceeds from disposal of property, plant and equipment | 1,076,973 | - |
| Purchase of intangible assets | (2,805) | (267,433) |
| Proceeds of investments | 3,711 | 3,626 |
| Loan repayments | 320 | - |
| Interest received | 6,091 | 6,135 |
| Cash provided by/(used in) investing activities | 744,525 | (1,263,068) |
| **Cash Flows from Financing Activities** | | |
| Long term loans repaid | (3,906,959) | (1,143,551) |
| Long term loans received | 5,005,860 | 4,377,815 |
| Repayments under a supplier finance arrangement | (409,183) | (977,522) |
| Lease repayments | (47,280) | (81,277) |
| Interest paid | (896,657) | (635,661) |
| Cash (used in)/provided by financing activities | (254,219) | 1,539,804 |
| Effect of changes in exchange rates on cash and cash equivalents | 574 | 9,141 |
| (Decrease)/Increase in cash and cash equivalents | (133,440) | 346,707 |
| Cash and cash equivalents at beginning of year | 405,804 | 2,794,431 |
| **CASH AND CASH EQUIVALENTS AT END OF PERIOD** | 272,364 | 3,141,138 |
| | | |
| **Cash and Cash Equivalents at end of period consists of:** | | |
| Cash and short-term investments | 645,761 | 3,178,438 |
| Bank overdraft | (373,397) | (37,300) |
| | 272,364 | 3,141,138 |

| | 3 Months to 2 August 2025 | | | |
|---|---|---|---|---|
| | **Jamaica Operations** | **US Operations** | **Eliminations** | **Group** |
| | **$'000** | **$'000** | **$'000** | **$'000** |
| External revenues | 14,693,585 | 11,494,944 | | 26,188,529 |
| Revenue from other segments | - | 1,242,255 | (1,242,255) | - |
| Total revenue | 14,693,585 | 12,737,199 | (1,242,255) | 26,188,529 |
| Segment result | 2,118,340 | 612,569 | 543,749 | 3,274,658 |
| Unallocated corporate expenses | | | | (661,617) |
| Operating profit | | | | 2,613,041 |
| Finance income | | | | 46,610 |
| Finance costs | | | | (951,673) |
| Profit before tax | | | | 1,707,978 |
| Taxation | | | | (112,702) |
| Net profit | | | | 1,595,276 |
| Segment assets - | | | | |
| Current assets | 25,510,279 | 11,408,625 | (5,581,491) | 31,337,413 |
| Non-current assets | 28,118,904 | 11,874,459 | (14,420,378) | 25,572,985 |
| Total assets | 53,629,183 | 23,283,084 | (20,001,869) | 56,910,398 |
| Segment liabilities - | | | | |
| Current liabilities | 34,337,046 | 35,740,541 | (6,244,299) | 63,833,288 |
| Non-current liabilities | 2,346,945 | 183,530 | (887,357) | 1,643,118 |
| Total liabilities | 36,683,991 | 35,924,071 | (7,131,656) | 65,476,406 |

| | 3 Months to 27 July 2024 - Restated | | | |
|---|---|---|---|---|
| | **Jamaica Operations** | **US Operations** | **Eliminations** | **Group** |
| | **$'000** | **$'000** | **$'000** | **$'000** |
| External revenues | 14,065,914 | 9,390,556 | - | 23,456,470 |
| Revenue from other segments | 31,577 | 1,351,329 | (1,382,906) | - |
| Total revenue | 14,097,491 | 10,741,885 | (1,382,906) | 23,456,470 |
| Segment result | 1,592,450 | 206,522 | 130,707 | 1,929,679 |
| Unallocated corporate expenses | | | | (949,679) |
| Operating profit | | | | 980,000 |
| Finance income | | | | 22,595 |
| Finance costs | | | | (653,025) |
| Profit before tax | | | | 349,570 |
| Taxation | | | | (213,087) |
| Net profit | | | | 283,598 |
| Segment assets - | | | | |
| Current assets | 23,002,059 | 8,758,071 | (4,310,005) | 27,450,125 |
| Non-current assets | 22,163,078 | 12,816,817 | (8,004,678) | 26,975,217 |
| Total assets | 45,165,137 | 21,574,888 | (12,314,683) | 54,425,342 |
| Segment liabilities - | | | | |
| Current liabilities | 26,402,828 | 31,728,576 | (4,521,075) | 53,610,329 |
| Non-current liabilities | 3,381,961 | 170,382 | (1,988,668) | 1,563,675 |
| Total liabilities | 29,784,789 | 31,898,958 | (6,509,743) | 55,174,004 |

## Accounting Periods

The company's financial year consists of 12 accounting periods ending on the Saturday closest to the calendar month end. The accounting year ends on the Saturday closest to May 1.

## Basis of Preparation

The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) under the historical cost convention, as modified by the revaluation of biological assets and certain financial assets.

These financial statements are presented in Jamaican dollars unless otherwise indicated.

The accounting policies followed in these interim financial statements are consistent with those used in the audited financial statements for the year ended 3 May 2025.

## Segmental Financial Information

Management has determined the operating segments based on the reports reviewed by the President and Chief Executive Officer that are used to make strategic decisions.

Segment information is provided for reportable segments as follows:

- Jamaica Operations
- US Operations

The business is considered primarily from a geographical perspective.

Finance income and Finance costs are not included in the measure of segment results and are not regularly reviewed by the President and Chief Executive Officer.

## Restatement

During the financial year, certain accounting irregularities were identified in our United States subsidiaries, resulting notably in inflated Inventories and Biological Assets.

An internal investigation was launched by the Group, which included a detailed review of the required corrections to the impacted balances, with the assistance of an independent advisory firm. Additionally, during the process to finalise the financial statements, irregularities were observed across the following financial statements line items with an impact on current and prior periods:

**Biological Assets, Inventories, Accounts Receivable and Cost of Sales**

- Unfounded journal entries

**Accounts Payable**

- Unfounded journal entries
- Identification of unrecorded liabilities.

The issues identified constituted material prior period errors and have been corrected by restating each of the financial statement line items information as at and for the year ended 27 April 2024 and as at 29 April 2023, for the cumulative effects of items related to periods prior to that date as shown in the tables below. As a result of these corrections, the following was noted:

**Taxation payable, Taxation recoverable, Deferred taxation and Taxation Expense**

- The income and deferred tax calculated for the affected periods were adjusted in the financial year ended 27 April 2024 and as at 29 April 2023.

**Borrowings**

- There were breaches of debt covenants for certain loans as at 27 April 2024 and 29 April 2023. These loans were reclassified from borrowings within non-current liabilities to borrowings within current liabilities for presentation purposes only, as is required by IFRS.

**Intangible Assets and Administrative expenses**

- Certain intangible assets including goodwill were deemed impaired as at 29 April 2023 and adjusted in the financial year ended 27 April 2024 and as at 29 April 2023.
- Amortisation was reversed through administrative expenses in the financial year ended 27 April 2024.

**Revenue and Other income**

- Amounts were reclassified from other income to revenue and cost of sales in the financial year ended 27 April 2024.

## Restatement (Continued)

### Liabilities under supplier finance arrangement

- Amounts were reclassified from accounts payable as at 27 April 2024 to a separate line item on the face of the balance sheet.

### Reserves

- The exchange differences on translating of foreign operations was revised based on all the adjustments made in the financials year ended 27 April 2024 and as at 29 April 2023.

Certain employees were separated from the Group and a temporary management team from within the Group was put in place to oversee the accounting and financial reporting processes within the U.S. Operations.

Management has implemented and enhanced internal controls and financial reporting oversight process to prevent future occurrences.

## Restatement (Continued)

*Consolidated Statement of Comprehensive Income for the quarter ended 27 July 2024*

| | | Restatement | |
|---|---|---|---|
| | **$'000** | **$'000** | **$'000** |
| Revenue | 23,451,760 | 4,710 | 23,456,470 |
| Cost of sales | (17,925,007) | (975,519) | (18,900,526) |
| Gross Profit | 5,526,753 | (970,809) | 4,555,944 |
| Other income | 59,485 | (4,710) | 54,775 |
| Administration and other expenses | (2,910,195) | 16,875 | (2,893,320) |
| Operating Profit | 1,938,644 | (958,644) | 980,000 |
| Profit/(Loss) before Taxation | 8,049,482 | (10,346,461) | (2,296,979) |
| Taxation | (213,087) | 147,115 | (65,972) |
| Net Profit | 1,095,127 | (811,529) | 283,598 |
| Other Comprehensive Income, net of taxes - | | | |
| Item that will be reclassified to profit or loss - | | | |
| Exchange differences on translating foreign operations | 25,924 | (37,055) | (11,131) |
| Total other comprehensive income | 25,924 | (37,055) | (11,131) |
| Total Comprehensive Income for Year | 1,121,051 | (848,584) | 272,467 |
| | | | |
| | $ | $ | $ |
| Loss per stock unit | 1.09 | (0.81) | 0.28 |

## Restatement (Continued)

*Consolidated Balance Sheet as at 27 July 2024*

| | | Restatement | |
|---|---|---|---|
| | $'000 | $'000 | $'000 |
| Non-Current Assets | | | |
| Intangible assets | 3,071,440 | (792,109) | 2,279,331 |
| Deferred income taxes | 155,326 | (128,025) | 27,301 |
| Total Non-Current Assets | 27,895,351 | (920,134) | 26,975,217 |
| | | | |
| Current Assets | | | |
| Inventories | 24,733,985 | (14,615,877) | 10,118,108 |
| Biological assets | 26,381,663 | (19,358,874) | 7,022,789 |
| Receivables | 6,892,747 | (629,291) | 6,263,456 |
| Taxation recoverable | 32,126 | 652,849 | 684,975 |
| Total Current Assets | 61,401,318 | (33,951,193) | 27,450,125 |
| | | | |
| Current Liabilities | | | |
| Payables | 16,274,018 | (926,063) | 15,347,955 |
| Liabilities under supplier finance arrangement | - | 1,264,049 | 1,264,049 |
| Taxation payable | 2,042,181 | (1,972,028) | 70,153 |
| Borrowings | 23,581,512 | 12,963,956 | 36,545,468 |
| Total Current Liabilities | 42,280,415 | 11,329,914 | 53,610,329 |
| | | | |
| Net current assets/(liabilities) | 19,120,903 | (45,281,107) | (26,160,204) |
| Capital employed | 47,016,254 | (46,201,241) | 815,013 |
| | | | |
| Stockholders' Equity | | | |
| Reserves | 3,233,890 | (616,644) | 2,617,246 |
| Retained earnings | 31,824,915 | (32,053,369) | (228,454) |
| Total Stockholders' Equity | 31,921,351 | (32,670,013) | (748,662) |
| | | | |
| Non-Current Liabilities | | | |
| Borrowings | 13,166,765 | (12,963,956) | 202,809 |
| Deferred income taxes | 1,482,305 | (567,272) | 915,033 |
| Total Current Liabilities | 15,094,903 | (13,531,228) | 1,563,675 |
| Total equity and non-current liabilities | 47,016,254 | (46,201,241) | 815,013 |

## Restatement (Continued)

*Consolidated Statement of Cash Flows as at 27 July 2024*

| | | Restatement | |
|---|---|---|---|
| | $'000 | $'000 | $'000 |
| Net profit | 1,095,127 | (811,529) | 283,598 |
| Amortisation | 34,934 | (10,566) | 24,368 |
| Taxation expense | 213,087 | (147,115) | 65,972 |
| Inventories | (789,853) | 537,058 | (252,795) |
| Biological assets | (413,207) | 418,648 | 5,441 |
| Receivables | (641,891) | 2,951,190 | 2,309,299 |
| Payables | 1,187,602 | (4,338,514) | (3,150,912) |
| Taxation paid | (384,595) | 2,517 | (382,078) |
| Cash used in operating activities | (916,063) | 976,893 | 60,830 |
| Repayments under a supplier finance arrangement | - | (977,522) | (977,522) |
| Cash provided by financing activities | 2,517,326 | (977,522) | 1,539,804 |
| Effect of changes in exchange rates on cash and cash | 8,512 | 629 | 9,141 |

The restatement had no impact on the investing cash flows and ending cash balances for 27 July 2024.